Prelude Therapeutics Inc (NASDAQ: PRLD) kicked off on Friday, up 11.46% from the previous trading day, before settling in for the closing price of $1.92. Over the past 52 weeks, PRLD has traded in a range of $0.61-$4.22.
During the last 5-year period, the sales drop of Healthcare Sector giant was -21.61%. While this was happening, its average annual earnings per share was recorded 20.44%. With a float of $27.77 million, this company’s outstanding shares have now reached $43.75 million.
Prelude Therapeutics Inc (PRLD) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Prelude Therapeutics Inc is 47.32%, while institutional ownership is 21.51%. The most recent insider transaction that took place on Mar 25 ’25, was worth 69,250. In this transaction Chief Chemistry Officer of this company bought 100,000 shares at a rate of $0.69, taking the stock ownership to the 480,123 shares. Before that another transaction happened on Mar 25 ’25, when Company’s CEO bought 675,000 for $0.69, making the entire transaction worth $467,438. This insider now owns 1,999,296 shares in total.
Prelude Therapeutics Inc (PRLD) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.37 earnings per share (EPS), higher than consensus estimate (set at -0.47) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.44% per share during the next fiscal year.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Take a look at Prelude Therapeutics Inc’s (PRLD) current performance indicators. Last quarter, stock had a quick ratio of 3.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Looking closely at Prelude Therapeutics Inc (NASDAQ: PRLD), its last 5-days average volume was 0.76 million, which is a jump from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 77.17%.
During the past 100 days, Prelude Therapeutics Inc’s (PRLD) raw stochastic average was set at 40.06%, which indicates a significant decrease from 96.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was lower than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.60, while its 200-day Moving Average is $1.10. However, in the short run, Prelude Therapeutics Inc’s stock first resistance to watch stands at $2.23. Second resistance stands at $2.32. The third major resistance level sits at $2.48. If the price goes on to break the first support level at $1.97, it is likely to go to the next support level at $1.81. Should the price break the second support level, the third support level stands at $1.72.
Prelude Therapeutics Inc (NASDAQ: PRLD) Key Stats
The company with the Market Capitalisation of 121.16 million has total of 62,865K Shares Outstanding. Its annual sales at the moment are 7,000 K in contrast with the sum of -127,170 K annual income. Company’s last quarter sales were recorded 6,500 K and last quarter income was -19,730 K.
